UNASSIGNED: To investigate the existing evidence on the effectiveness of approaches to treating @entity5589 and to assess the methodological quality of this evidence. The Cochrane Controlled Trials Register (CENTRAL), Medline, Embase, Cinahl, Physiotherapy Evidence (Pedro), McMaster and Web of Science databases were searched. The references of identified articles and reviews were also checked for relevancy. The methodological quality was assessed according to the Cochrane Collaboration's domain-based evaluation framework. Of the 331 identified records, 10 were considered relevant for a qualitative analysis. The risk of bias was considered being low for six studies and high for four. Eight studies were randomized controlled trials, and two were controlled clinical trials. In the samples, male gender predominated, and the mean age of the @entity1 varied from 51 to 72  years. The duration of intervention varied from 3 to 17  months. One small trial on the effect of @entity7786 reported a significant positive result. The other trials observed no improvement or insignificant improvement among the @entity1 treated with intravenous immunoglobulin, @entity1499 , etanercept or interferon. Thus far, there is no evidence indicating that any specific treatment is the effective in treating @entity5589 .

Medication of XXXX : a systematic review.

@entity1 :: ('9606', 'Species') :: ['participants'] @entity7786 :: ('MESH:D010074', 'Chemical') :: ['oxandrolone'] @entity5589 :: ('MESH:D018979', 'Disease') :: ['inclusion body myositis'] @entity1499 :: ('MESH:D008727', 'Chemical') :: ['methotrexate']
@entity5589 :: (MESH:D018979,Disease) :: ['inclusion body myositis']
